XCX (XelebProtocol) 24-hour amplitude 108.5%: BinanceAlpha tops the gainers list, coordinated with whale inflows for price pumping
Bitget Pulse2026/04/10 22:02Volatility Brief
In the past 24 hours, XCX price surged from a low of $0.004222 to a high of $0.009065-$0.01137 (according to different platforms), and is currently quoted at around $0.006647, with a price fluctuation range of 108.5%-114.7%. The 24-hour trading volume skyrocketed to $3.12-$13.5 million, with a peak between $4.7-$5.86 million, DEX liquidity around $440,000, and a market cap of about $700,000-$990,000.
Brief Analysis of Abnormal Movement Reasons
- Top Gainer on Binance Alpha: XCX topped the 24-hour gainer list (201%-415%), with official accounts and community discussions fueling the hype.
- Whale Inflows and Smart Money Rotation: On-chain monitoring indicates coordinated whale funds pumping the price, aggressive position rotation by smart money, and a significant liquidity injection into a new DEX pool within 36 hours.
- Active Trading Platforms: The XCX/USDT pair on Gate.io saw 634% volatility, with peak trading volumes standing out across multiple platforms.
Market Opinion and Outlook
The X community on X Platform considers XCX the top gainer of the day (+354%), with several exchanges promoting its AI agent economy and PoU model. However, it is emphasized that after high volatility, a pullback (-48%) is already evident. Mainstream sentiment remains cautious, warning that low market cap tokens are easily manipulated by whales and short-term volatility may persist.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million
RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.
Ledger CTO urges crypto holders to update iPhones after DarkSword exploit revealed
Crypto ICOs Left in Limbo After CLARITY Act Fails in Senate